Nurix Therapeutics (NASDAQ:NRIX) Stock: Insider Julia Gregory Sells 22,583 Shares

October 15, 2026 by InsiderTrades.com

Key Points

Director Julia Gregory sold 22,583 shares of Nurix Therapeutics at an average price of $23.40, generating approximately $528,000 and reducing her direct holdings by 67.75%.
Nurix reported quarterly earnings of $4.73 per share, far exceeding the $0.60-per-share loss analysts expected, while revenue reached $673.06 million versus a $24.35 million consensus estimate.
Analysts remain broadly optimistic, with 13 Buy ratings and a consensus price target of $34.64 compared with the stock’s recent price near $23.67; however, rising operating expenses and reliance on Roche present risks.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) Director Julia Gregory sold 22,583 shares of the firm's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total transaction of $528,442.20. Following the completion of the sale, the director owned 10,750 shares in the company, valued at $251,550. This represents a 67.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Nurix Therapeutics Price Performance

Nurix Therapeutics stock opened at $23.67 on Thursday. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of 10.25 and a beta of 1.82. Nurix Therapeutics, Inc. has a 1-year low of $9.18 and a 1-year high of $28.23. The business has a fifty day moving average price of $25.14 and a 200-day moving average price of $21.06.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, topping the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 62.20%. The company had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. On average, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.69 earnings per share for the current fiscal year.

More Nurix Therapeutics News

Here are the key news stories impacting Nurix Therapeutics this week:

Positive Sentiment: Analysts remain constructive on Nurix’s outlook. Robert W. Baird raised its price target to $36 and maintained an “outperform” rating, while Needham reaffirmed a “buy” rating with a $34 target. Truist kept a “buy” rating despite trimming its target to $33. These targets imply substantial potential upside from recent trading levels. Nurix Therapeutics Q3 2026 Earnings
Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 study of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst reiterated a “Strong Buy,” citing promising Phase 1/2 data, possible accelerated approval, partnerships and multiple development pathways. Nurix Strong Buy Analysis
Positive Sentiment: RBC Capital Markets said Nurix’s enterprise value remains underappreciated, supporting the view that the stock’s valuation does not fully reflect its pipeline and commercial potential. RBC Capital Markets Valuation Commentary
Neutral Sentiment: Nurix reported quarterly earnings well above consensus, largely reflecting unusually high revenue compared with estimates. However, the earnings reaction was pressured by rising operating expenses, highlighting continued investment needs for its clinical programs. Nurix Q3 Earnings and Operating Expenses
Negative Sentiment: Director Julia P. Gregory sold 22,583 shares for approximately $528,000, reducing her direct holdings by 67.75%. Although insider sales can be made for personal or diversification reasons, the transaction may weigh modestly on sentiment. SEC Insider Trading Filing
Negative Sentiment: Nurix faces execution and financial risks from its reliance on Roche for bexobrutideg, including cost burdens, reduced control and uncertain future returns. Nurix Roche Reliance Risk Analysis

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada cut their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set an "outperform" rating on the stock in a research note on Tuesday. Robert W. Baird boosted their target price on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an "outperform" rating in a research report on Tuesday. BTIG Research restated a "buy" rating and set a $32.00 target price on shares of Nurix Therapeutics in a research report on Friday, July 10th. UBS Group upped their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, July 22nd. Finally, Mizuho increased their price target on Nurix Therapeutics from $30.00 to $34.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $34.64.

Get Our Latest Report on NRIX

Institutional Investors Weigh In On Nurix Therapeutics

Large investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Nurix Therapeutics during the second quarter worth approximately $212,769,000. General Atlantic L.P. acquired a new position in Nurix Therapeutics during the fourth quarter worth $92,899,000. Baker BROS. Advisors LP grew its holdings in Nurix Therapeutics by 20.0% in the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company's stock valued at $88,373,000 after buying an additional 776,431 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Nurix Therapeutics by 4.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,710,877 shares of the company's stock valued at $57,519,000 after buying an additional 155,000 shares in the last quarter. Finally, Trails Edge Capital Partners LP purchased a new stake in Nurix Therapeutics in the 2nd quarter valued at $38,166,318.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix's pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton's tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.